BR112023020562A2 - Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina - Google Patents
Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotinaInfo
- Publication number
- BR112023020562A2 BR112023020562A2 BR112023020562A BR112023020562A BR112023020562A2 BR 112023020562 A2 BR112023020562 A2 BR 112023020562A2 BR 112023020562 A BR112023020562 A BR 112023020562A BR 112023020562 A BR112023020562 A BR 112023020562A BR 112023020562 A2 BR112023020562 A2 BR 112023020562A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- small cell
- cell lung
- lung carcinoma
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171536P | 2021-04-06 | 2021-04-06 | |
| US202163171571P | 2021-04-06 | 2021-04-06 | |
| PCT/US2022/023629 WO2022216796A1 (en) | 2021-04-06 | 2022-04-06 | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020562A2 true BR112023020562A2 (pt) | 2023-12-05 |
Family
ID=83510391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020562A BR112023020562A2 (pt) | 2021-04-06 | 2022-04-06 | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12433951B2 (https=) |
| EP (1) | EP4319811A1 (https=) |
| JP (1) | JP2024514506A (https=) |
| BR (1) | BR112023020562A2 (https=) |
| CA (1) | CA3214989A1 (https=) |
| MX (1) | MX2023011733A (https=) |
| WO (1) | WO2022216796A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024243450A1 (en) * | 2023-05-23 | 2024-11-28 | Abbvie Inc. | Methods of treatment using anti-c-met antibody drug conjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| EP3448427A1 (en) * | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| WO2020065396A1 (en) | 2018-09-26 | 2020-04-02 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
-
2022
- 2022-04-06 BR BR112023020562A patent/BR112023020562A2/pt unknown
- 2022-04-06 US US17/714,724 patent/US12433951B2/en active Active
- 2022-04-06 CA CA3214989A patent/CA3214989A1/en active Pending
- 2022-04-06 WO PCT/US2022/023629 patent/WO2022216796A1/en not_active Ceased
- 2022-04-06 JP JP2023560513A patent/JP2024514506A/ja active Pending
- 2022-04-06 MX MX2023011733A patent/MX2023011733A/es unknown
- 2022-04-06 EP EP22785354.6A patent/EP4319811A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022253888A9 (en) | 2024-02-22 |
| MX2023011733A (es) | 2023-10-13 |
| CA3214989A1 (en) | 2022-10-13 |
| US12433951B2 (en) | 2025-10-07 |
| EP4319811A1 (en) | 2024-02-14 |
| AU2022253888A1 (en) | 2023-09-28 |
| WO2022216796A1 (en) | 2022-10-13 |
| JP2024514506A (ja) | 2024-04-02 |
| US20220323597A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| EA202091539A1 (ru) | Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1 | |
| CY1114552T1 (el) | Αντινεοπλασματικοι συνδυασμοι που περιεχουν ηκι-272 και βινορελμπινη | |
| CY1118602T1 (el) | Αντινεοπλασματικοι συνδυασμοι 4-ανιλινο-3-κυανοκινολινων και καπεσιταβινης | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| PH12021552395A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions | |
| BR112021008549A2 (pt) | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor | |
| EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
| BR112022017508A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| MX385778B (es) | Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
| NO20084047L (no) | Forbedrede anti-tumor behandlinger | |
| BR112021014636A2 (pt) | Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão | |
| EA201992575A1 (ru) | Биомаркеры для терапии рака | |
| MX2021002241A (es) | Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1). | |
| HK1247577A1 (zh) | Egfr突变阳性的非小细胞肺癌的联合疗法 | |
| BR112021022806A2 (pt) | Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| CL2020003204A1 (es) | Tratamiento de nsclc en etapa iii y mitigación de condiciones patológicas asociadas al tratamiento | |
| MX2024006765A (es) | Terapia de combinación con adc ceacam5 - anti-pd1/pd-l1. | |
| BR112023020562A2 (pt) | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina | |
| MX2023007918A (es) | Uso de un inhibidor de kras g12c en el tratamiento de canceres. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY (IE) |